Logo

Shares in Sequenom Up 9.5 Percent on News of Qiagen Dx Alliance

Jan 08, 2007
NEW YORK (GenomeWeb News) — Shares in Sequenom were up 9.51 percent, or $.45, at $5.18, in mid-afternoon trading today after the company said it will work with Qiagen to develop a preanalytical product to enrich nucleic acids for prenatal diagnostics.
 
As GenomeWeb News reported this morning, Sequenom will retain commercial rights to any tests the companies develop under the partnership.
 
Qiagen said the goal for the partnership is to develop reliable reagents for the enrichment of small nucleic acid fragments, such as those found in maternal plasma, to analyze cancer and other disorders.
Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.